Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Both Novo Nordisk and Eli Lilly are studying their weight loss drugs to treat fatty liver disease, chronic kidney disease, ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Chesapeake Regional Healthcare in Virginia was indicted for healthcare fraud involving unnecessary surgical procedures.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, Mounjaro and Zepbound, remains massive, their sales were hurt due to ...